ASCO 2022: Nimotuzumab Plus Gemcitabine for KRAS Wild-Type Pancreatic Cancer
Posted: 06/22/2022 | By: Chase Doyle

Question 1 of 5

In the full-analysis set, patients with KRAS wild-type locally advanced or metastatic pancreatic cancer who received nimotuzumab combined with gemcitabine had a median overall survival of how many months?

Choose 1